FLT
Los inhibidores de la FLT (quinasa de tirosina similar a Fms) son compuestos que se dirigen a los receptores FLT, los cuales están involucrados en la regulación de la angiogénesis a través de la vía del VEGF (factor de crecimiento endotelial vascular). Los receptores FLT desempeñan un papel crucial en el desarrollo de nuevos vasos sanguíneos en los tumores. Inhibir los receptores FLT puede reducir eficazmente la angiogénesis y el crecimiento tumoral, lo que hace que estos inhibidores sean importantes en la terapia contra el cáncer. En CymitQuimica, ofrecemos una selección de inhibidores de FLT de alta calidad para apoyar su investigación en oncología, biología vascular y angiogénesis.
Se han encontrado 92 productos de "FLT"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
TG-46
CAS:<p>TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.</p>Fórmula:C26H34N6O3SPureza:98.82% - 99.81%Forma y color:SolidPeso molecular:510.65FLT3-IN-6
CAS:<p>FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.</p>Fórmula:C23H25N5O3Forma y color:SolidPeso molecular:419.48JNJ-47117096 hydrochloride
CAS:<p>JNJ-47117096 hydrochloride is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM.</p>Fórmula:C21H23ClN4O2Forma y color:SolidPeso molecular:398.89FLT3-IN-12
CAS:<p>FLT3-IN-12: potent, selective oral FLT3 inhibitor; FLT3-WT IC50: 1.48 nM, FLT3-D835Y: 2.87 nM; >1000x selective over c-KIT; anti-AML, IC50: 0.75 nM MV4-11.</p>Fórmula:C21H23F3N6OForma y color:SolidPeso molecular:432.44FLT3-IN-15
CAS:<p>FLT3-IN-15 is an orally active and potent FLT3 inhibitor, capable of acting on FLT3 (IC50: 0.87 nM) and FLT3/D835Y (IC50: 0.32 nM).</p>Fórmula:C22H23ClFN5O2Forma y color:SolidPeso molecular:443.91PDGFRα/FLT3-ITD-IN-2
CAS:<p>PDGFRα/FLT3-ITD-IN-2 is a potent inhibitor of PDGFRα (IC50>20 μM) and FLT3 (IC50: 0.004 μM).</p>Fórmula:C28H41N9OForma y color:SolidPeso molecular:519.68FLT3-IN-18
CAS:<p>FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.</p>Fórmula:C26H36N8OForma y color:SolidPeso molecular:476.62FLT3/D835Y-IN-1
CAS:<p>FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.</p>Fórmula:C22H21N5O3Forma y color:SolidPeso molecular:403.43AGL 2043
CAS:<p>AGL 2043 is a potent, reversible, ATP-competitive inhibitor of type III receptor tyrosine kinases.</p>Fórmula:C15H12N4SForma y color:SolidPeso molecular:280.35MDK5466
CAS:<p>MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.</p>Fórmula:C21H23N3OSPureza:98%Forma y color:SolidPeso molecular:365.49PDGFRα/FLT3-ITD-IN-1
CAS:<p>PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.</p>Fórmula:C27H39N9OForma y color:SolidPeso molecular:505.66BSc5371
CAS:<p>BSc5371: Irreversible FLT3 inhibitor; Kds 0.83-5.8 nM for various FLT3 mutants including wild type.</p>Fórmula:C24H31N5O4SPureza:98%Forma y color:SolidPeso molecular:485.6PDGFRα/FLT3-ITD-IN-3
CAS:<p>PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα (IC50: 0.153 μM), FLT3 (IC50: 0.004 μM) and PDGFRα/FLT3-ITD-IN-3 has the potential to be</p>Fórmula:C26H39N9Forma y color:SolidPeso molecular:477.65FLT3-IN-11
CAS:<p>FLT3-IN-11, an oral FLT3 kinase inhibitor: potent, selective, IC50 - wild-type 7.22 nM, FLT3-D835Y 4.95 nM, anti-AML IC50 3.2 nM for MV4-11.</p>Fórmula:C20H25F3N6OForma y color:SolidPeso molecular:422.45HP1328
CAS:<p>HP1328: potent FLT3/ITD inhibitor, reduces leukemia, extends survival in mice, belongs to benzoimidazole family.</p>Fórmula:C23H23N3O3Forma y color:SolidPeso molecular:389.45FLT3/ITD-IN-2
CAS:<p>FLT3/ITD-IN-2: Powerful FLT3/ITD, FLT3D835Y, and FLT3 inhibitor; hinders AML cell growth. IC50s: 0.3-1.0 nM.</p>Fórmula:C23H26F3N7O2Forma y color:SolidPeso molecular:489.49KRN383
CAS:<p>KRN383 inhibits ITD cell growth at ≤2.9 nM, erases ITD tumors in mice at 80 mg/kg dose, and may suit various treatment plans.</p>Fórmula:C17H17N3O4Forma y color:SolidPeso molecular:327.33Gilteritinib hemifumarate
CAS:<p>Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of</p>Fórmula:C29H44N8O3C4H4O4Pureza:99.78%Forma y color:SolidPeso molecular:610.75AXL-IN-13
CAS:<p>AXL-IN-13: potent, oral AXL inhibitor, IC50=1.6nM, Kd=0.26nM, anti-cancer, inhibits EMT, cell migration & invasion.</p>Fórmula:C34H41FN6O5Pureza:99.20%Forma y color:SolidPeso molecular:632.72AC710
CAS:<p>AC710 is a potent PDGFR inhibitor (Kds: 0.6, 1, 1.57, 1.3, 1 nM for FLT3, KIT, CSF1R, PDGFRα and PDGFRβ).</p>Fórmula:C31H42N6O4Pureza:99.67%Forma y color:SolidPeso molecular:562.7FLT3-IN-4
CAS:<p>FLT3-IN-4 (FLT3 inhibitor 9u) is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor ,for treating acute myelogenous</p>Fórmula:C23H25N7O2Pureza:99.9%Forma y color:SolidPeso molecular:431.49FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Fórmula:C22H25N9OPureza:97.4%Forma y color:SolidPeso molecular:431.49AAE871
CAS:<p>AAE871 is a type I FLT3 inhibitor.</p>Fórmula:C24H34N8O2SForma y color:SolidPeso molecular:498.64LBW242
CAS:<p>LBW242: oral 3-mer Smac mimetic, IAP inhibitor, targets multiple myeloma, enhances TRAIL/chemo death in ovarian cancer, active on mutant FLT3 cells.</p>Fórmula:C27H42N4O2Pureza:98%Forma y color:SolidPeso molecular:454.65FLT3/ITD-IN-3
CAS:<p>FLT3/ITD-IN-3 (Compound 19) is a potent FLT3-ITD inhibitor with IC50 values: FLT3D835Y (0.3 nM), FLT3 (0.4 nM), inhibits AML cell proliferation.</p>Fórmula:C22H26ClN7O2Forma y color:SolidPeso molecular:455.94GTP-14564
CAS:<p>GTP-14564 is a novel tyrosine kinase inhibitor that also inhibits wt-FLT3 and ITD-FLT3.</p>Fórmula:C15H10N2OPureza:99.69%Forma y color:SolidPeso molecular:234.25TG-89
CAS:<p>TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and</p>Fórmula:C26H34N6O3SPureza:98.68%Forma y color:SolidPeso molecular:510.65OTS447
CAS:<p>OTS447 is a potent FLT3 inhibitor (IC50: 21 nM) with potential anticancer activity for cancer research .</p>Fórmula:C27H32ClN3O2Pureza:98.78%Forma y color:SolidPeso molecular:466.02UNC4203
CAS:<p>UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.</p>Fórmula:C30H44N6OForma y color:SolidPeso molecular:504.71FLT3/ITD-IN-5
CAS:<p>FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.</p>Fórmula:C23H25N7O2Forma y color:SolidPeso molecular:431.49TAK-659
CAS:<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Fórmula:C17H21FN6OPureza:98%Forma y color:SolidPeso molecular:344.39HPK1-IN-2 dihydrochloride
CAS:<p>HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].</p>Fórmula:C19H22Cl2N6OSForma y color:SolidPeso molecular:453.39SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Fórmula:C28H35ClFN7O3SForma y color:SolidPeso molecular:604.14Lomonitinib
CAS:<p>Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.</p>Fórmula:C27H24N4O2Forma y color:SolidPeso molecular:436.505Multi-kinase inhibitor 3
CAS:<p>Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.</p>Fórmula:C26H26N6O2Forma y color:SolidPeso molecular:454.52FLT3/ITD-IN-1
<p>FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.</p>Fórmula:C19H22N6O2Forma y color:SolidPeso molecular:366.42TAS05567
CAS:<p>TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).</p>Fórmula:C21H29N9O2Pureza:98%Forma y color:SolidPeso molecular:439.51JNJ-47117096
CAS:<p>JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.</p>Fórmula:C21H22N4O2Forma y color:SolidPeso molecular:362.425E6201
CAS:<p>E6201, a dual kinase inhibitor, blocks MEK1/FLT3 and has anti-tumor/psoriasis effects with low IC50s: ERK2 (5.2 nM), JNK (91 nM), p38 MAPK (19 nM).</p>Fórmula:C21H27NO6Forma y color:SolidPeso molecular:389.44LT-850-166
<p>LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.</p>Fórmula:C30H29Cl2N7OForma y color:SolidPeso molecular:574.5TTT 3002
CAS:<p>TTT 3002: oral FLT3 inhibitor for AML research, blocks D835 mutations, potent at 0.2 nM IC50.</p>Fórmula:C27H23N5O3Forma y color:SolidPeso molecular:465.50Multi-kinase inhibitor 4
CAS:<p>Multi-kinase inhibitor 4 (compound 14) serves as an orally effective inhibitor targeting FLT1, KDR, FLT3, FLT4, PDGFRα, and PDGFRβ, exhibiting IC50 values of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, and 0.89 nM respectively. This compound plays a crucial role in cancer research.</p>Fórmula:C25H24N6O2Forma y color:SolidPeso molecular:440.50
